Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes

Diabetes Care

Volumn 38, Issue 12, 2015, Pages 2258-2265

  Henry, Robert R ^a,b   Thakkar, Payal ^c   Tong, Cindy ^c   Polidori, David ^d   Alba, Maria ^c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; PLACEBO; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC KETOACIDOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY TRACT INFECTION; VAGINA MYCOSIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84962362243     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1730     Document Type: Article

References (30)

1. Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: A position statement of the American Diabetes Association. Diabetes Care 2014;37:2034-2054.
2. Aschner P, Horton E, Leiter LA, Munro N, Skyler JS; Global Partnership for Effective Diabetes Management. Practical steps to improving the management of type 1 diabetes: Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2010;64:305-315.
3. Livingstone SJ, Levin D, Looker HC, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313:37-44.
4. Trachtenbarg DE. Diabetic ketoacidosis. Am Fam Physician 2005;71:1705-1714.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl JMed 1993;329:977-986.
6. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
7. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978.
8. SYMLIN (pramlintide acetate) injection for subcutaneous use [package insert]. Wilmington, DE, AstraZeneca Pharmaceuticals LP; 2015.
9. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus: Rationale and review of clinical data. Drugs 2004;64:1419-1432.
10. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: A sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 25 August 2015 [Epub ahead of print]. DOI:10.1111/nyas.12852.
11. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-545.
12. Sha S, DevineniD, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-672.
13. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozintreated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:E867-E871.
14. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: Pooled analysis of phase 3 study results. Postgrad Med 2014; 126:16-34.
15. INVOKANA (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ, Janssen Pharmaceuticals; 2014.
16. Neal B, Perkovic V, de ZeeuwD, et al.; CANVAS Trial Collaborative Group. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38:403-411.
17. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419.
18. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-1483.
19. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181-1188.
20. Borus JS, Laffel L. Adherence challenges in the management of type 1 diabetes in adolescents: Prevention and intervention. Curr Opin Pediatr 2010;22:405-411.
21. Perilli G, Saraceni C, Daniels MN, Ahmad A. Diabetic ketoacidosis: A reviewand update. Curr Emerg Hosp Med Rep 2013;1:10-17.
22. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patientwith a low-carbohydrate diet. J Diabetes Invest 2015;6:587-590.
23. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [article online], 2015. Available from http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed 19 May 2015.
24. EuropeanMedicines Agency (EMA). Reviewof diabetesmedicines called SGLT2 inhibitors started. Risk of diabetic ketoacidosis to be examined [article online], 2015. Available fromhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2-inhibitors/human-referral-prac-000052.jsp&mid=WC0b01ac05805c516f. Accessed 25 June 2015.
25. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693.
26. Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf 2015;14:795-800.
27. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680-1686.
28. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response tosodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
29. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-514.
30. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015; 21:512-517.